115 related articles for article (PubMed ID: 3864428)
1. Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser.
Miners JO; Wing LM; Birkett DJ
Aust N Z J Med; 1985 Jun; 15(3):348-9. PubMed ID: 3864428
[TBL] [Abstract][Full Text] [Related]
2. Lack of relationship between tolbutamide metabolism and debrisoquine oxidation phenotype.
Peart GF; Boutagy J; Shenfield GM
Eur J Clin Pharmacol; 1987; 33(4):397-402. PubMed ID: 3443146
[TBL] [Abstract][Full Text] [Related]
3. Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition.
Robson RA; Miners JO; Whitehead AG; Birkett DJ
Br J Clin Pharmacol; 1987 Jun; 23(6):772-5. PubMed ID: 3606937
[TBL] [Abstract][Full Text] [Related]
4. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.
Fuhr U; Jetter A; Kirchheiner J
Clin Pharmacol Ther; 2007 Feb; 81(2):270-83. PubMed ID: 17259951
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies.
Robson RA; Miners JO; Matthews AP; Stupans I; Meller D; McManus ME; Birkett DJ
Biochem Pharmacol; 1988 May; 37(9):1651-9. PubMed ID: 3288213
[TBL] [Abstract][Full Text] [Related]
6. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
7. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K
Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141
[TBL] [Abstract][Full Text] [Related]
8. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
9. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.
Miners JO; Smith KJ; Robson RA; McManus ME; Veronese ME; Birkett DJ
Biochem Pharmacol; 1988 Mar; 37(6):1137-44. PubMed ID: 3355588
[TBL] [Abstract][Full Text] [Related]
10. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
Philip PA; James CA; Rogers HJ
Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
[TBL] [Abstract][Full Text] [Related]
11. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
12. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition.
Knodell RG; Hall SD; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1987 Jun; 241(3):1112-9. PubMed ID: 3598900
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
15. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
16. Effect of levomepromazine and metabolites on debrisoquine hydroxylation in the rat.
Hals PA; Dahl SG
Pharmacol Toxicol; 1994 Nov; 75(5):255-60. PubMed ID: 7870695
[TBL] [Abstract][Full Text] [Related]
17. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man.
Miners JO; Wing LM; Lillywhite KJ; Robson RA
Br J Clin Pharmacol; 1985 Sep; 20(3):219-23. PubMed ID: 4041342
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone.
Silas JH; Tucker GT; Smith AJ; Fieller NR
Br J Clin Pharmacol; 1980 Apr; 9(4):419-25. PubMed ID: 7378259
[No Abstract] [Full Text] [Related]
19. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
